• Age at time of screening according to diabetes type:

  • T1D:   7-85 years

  • T2D: 18-85 years

• Has a clinical diagnosis minimum per diabetes type:

• Type 1 Diabetes: Diagnosis of T1D for at least 6 months

• Type 2 Diabetes: Diagnosis of insulin-requiring T2D for 1 year or more

• Willing to wear the system continuously throughout the study.

• Has a Glycosylated hemoglobin (HbA1c) equal to or less than 11.0% (as processed by Central Lab) at time of screening visit.

• Is willing to take one of the following insulins and can financially support the use of insulin preparations as required by the study:

  • Humalog™* (insulin lispro injection)

  • NovoLog™*/NovoRapid™* (insulin aspart solution for injection)

  • Admelog™* (insulin lispro injection)

  • Merilog™* (insulin aspart)

  • Authorized generic insulin aspart

  • Authorized generic insulin lispro

Gain access to cutting-edge medications and treatments before they are widely available.

Our expert team is under the guidance of renowned endocrinologist, Dr. Anastasios Manessis.

We are highly focused on patient well-being and the highest ethical standards in clinical research.